Genome-wide characterization of circulating metabolic biomarkers reveals substantial pleiotropy and novel disease pathways
ABSTRACT
Genome-wide association analyses using high-throughput metabolomics platforms have led to novel insights into the biology of human metabolism1–7. This detailed knowledge of the genetic determinants of systemic metabolism has been pivotal for uncovering how genetic pathways influence biological mechanisms and complex diseases8–11. Here we present a genome-wide association study of 233 circulating metabolic traits quantified by nuclear magnetic resonance spectroscopy in up to 136,016 participants from 33 predominantly population-based cohorts. We discover over 400 independent loci and assign likely causal genes at two-thirds of these using detailed manual curation of highly plausible biological candidates. We highlight the importance of sample- and participant characteristics, such as fasting status and sample type, that can have significant impact on genetic associations, revealing direct and indirect associations on glucose and phenylalanine. We use detailed metabolic profiling of lipoprotein- and lipid-associated variants to better characterize how known lipid loci and novel loci affect lipoprotein metabolism at a granular level. We demonstrate the translational utility of comprehensively phenotyped molecular data, characterizing for the first time the metabolic associations of an understudied phenotype, intrahepatic cholestasis of pregnancy. Finally, we observe substantial genetic pleiotropy for multiple metabolic pathways and illustrate the importance of careful instrument selection in Mendelian randomization analysis, revealing a putative causal relationship between acetoacetate and hypertension. Our publicly available results provide a foundational resource for the community to examine the role of metabolism across diverse diseases.
Competing Interest Statement
The authors declare the following competing interests: During the course of the project P.S. became a full-time employee of GlaxoSmithKline. V.S. has received a honorarium from Sanofi for consulting. V.S. also has ongoing research collaboration with Bayer Ltd (All outside the present study). As of January 2020, A.M. is the employee of Genentech, and holder of Roche stock. N.v.Z. is currently employed by AstraZeneca PLC and is a shareholder in AstraZeneca. R.L.-G. is a part-time contractor of Metabolon Inc. During the course of the project J.Z. became a full-time employee of Novartis. A.I.d.H. is currently an employee of AbbVie. C.M. is funded by the Chronic Disease Research Foundation (CDRF). T.D.S. is co-founder and shareholder of ZOE ltd. As of June 2019, M.I.M. is the employee of Genentech, and holder of Roche stock. J.D. serves on scientific advisory boards for AstraZeneca, Novartis, and UK Biobank, and has received multiple grants from academic, charitable and industry sources outside of the submitted work. A.S.B. reports institutional grants outside of this work from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and Sanofi. Other authors declare no competing interests.
Funding Statement
This is a multi-centre study. All relevant funding is indicated in the Supplementary Notes of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a multi-centre study. The studies included in this work have been approved by the relevant Ethics Committees of all participating studies as stated in the manuscript.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. The data will be made publicly available at the time of final publication.
Subject Area
- Addiction Medicine (354)
- Allergy and Immunology (679)
- Anesthesia (182)
- Cardiovascular Medicine (2685)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12318)
- Forensic Medicine (10)
- Gastroenterology (771)
- Genetic and Genomic Medicine (4161)
- Geriatric Medicine (390)
- Health Economics (685)
- Health Informatics (2699)
- Health Policy (1010)
- Hematology (365)
- HIV/AIDS (861)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3935)
- Nursing (213)
- Nutrition (586)
- Oncology (2073)
- Ophthalmology (596)
- Orthopedics (243)
- Otolaryngology (308)
- Pain Medicine (253)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1131)
- Primary Care Research (462)
- Public and Global Health (6583)
- Radiology and Imaging (1424)
- Respiratory Medicine (877)
- Rheumatology (414)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (55)
- Transplantation (191)
- Urology (170)